Lercaprel (Enalapril Maleate, Lercanidipine Hydrochloride)

Enalapril maleate is converted in the body to enalaprilat, which inhibits the angiotensin‑converting enzyme (ACE). By blocking ACE, the formation of angiotensin II—a potent vasoconstrictor—is reduced, leading to vasodilation, decreased aldosterone secretion, and lower sodium and water retention. The result is a reduction in systemic vascular resistance and blood pressure.

The dosage of Lercaprel is individualized by the prescribing healthcare professional based on the patient’s blood‑pressure level, response, and tolerability. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during therapy. Patients should follow the exact instructions provided on the prescription label and consult their clinician for any changes.

Safety of Lercaprel during pregnancy and lactation has not been fully established. ACE inhibitors are generally contraindicated in the second and third trimesters because of potential fetal toxicity, and calcium‑channel blockers should be used only if the benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, visit the product page for Lercaprel on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and assistance with import documentation.

Compared with single‑agent therapies, Lercaprel offers the convenience of two complementary mechanisms in one tablet, potentially improving blood‑pressure control and adherence. ACE inhibitor‑only products lack calcium‑channel blockade, while calcium‑channel blocker‑only agents do not inhibit the renin‑angiotensin system. The combination may be more effective in patients who need both vasodilation and reduced angiotensin‑II activity, but individual response varies.

Lercaprel tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date indicated on the label. No refrigeration is required for this oral formulation.

Lercaprel is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised. Patients should follow the dosing schedule prescribed and avoid missing doses, as consistent intake helps maintain stable blood‑pressure control.

The most serious adverse reactions to watch for include angioedema (swelling of the lips, tongue, or airway), severe hypotension, hyperkalemia, acute renal impairment, hepatic dysfunction, and neutropenia. If any of these symptoms occur—such as difficulty breathing, sudden drop in blood pressure, swelling, or signs of infection—medical attention should be sought immediately.

Lercaprel is contraindicated in patients with known hypersensitivity to enalapril, lercanidipine, or any component of the formulation. It should also be avoided in individuals with a history of angioedema related to ACE‑inhibitor therapy, severe renal impairment, or those already receiving another ACE inhibitor or ARB. Clinicians must assess each patient’s medical history before initiating therapy.